MarkCCascioneMD

PubMed

• 1 citations
  Podcast on the Challenges and Recommendations to Address Unmet Needs in MS for LGBTQ+ Populations in the United States.
  William L Conte, Mark Cascione, Amy B Sullivan> ;Neurology and Therapy. 2023 Oct 1
• 27 citations
  Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
  Erin E. Longbrake, Yang Mao-Draayer, Mark Cascione, Tomasz Zielinski, Eris Bame, David Brassat, Chongshu Chen, Shivani Kapadia, Jason P. Mendoza, Catherine Miller, Bec...> ;Multiple Sclerosis. 2021 May 1
• 7 citations
  Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
  Patrick Vermersch, Jiwon Oh, Mark Cascione, Celia Oreja-Guevara, Claudio Gobbi, Lori H. Travis, Kjell-Morten Myhr, Patricia K. Coyle> ;Multiple Sclerosis and Related Disorders. 2020 Aug 1
• 1 citations
  Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰
  Samuel F. Hunter, Florian P. Thomas, Mark Cascione, Ian M. Williams, Xiangyi Meng, Lesley Schofield, Jamie L. Weiss, Nadia Tenenbaum, Bruce A.C. Cree, Preferms investi...> ;Multiple Sclerosis and Related Disorders. 2020 Oct 1
• 12 citations
  Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relaps...
  Anthony Traboulsee, David K.B. Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller> ;BMC Neurology. 2018 Sep 14
• 9 citations
  Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
  Mark Cascione, Nadia Tenenbaum, Jeanette Wendt, Xiangyi Meng, Lesley Schofield, Bruce A.C. Cree, Preferms investigators> ;Multiple Sclerosis and Related Disorders. 2018 Jul 11
• 21 citations
  Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial:
  Bruce A.C. Cree, Douglas L. Arnold, Mark Cascione, Edward Fox, Ian M. Williams, Xiangyi Meng, Lesley Schofield, Nadia Tenenbaum> ;Therapeutic Advances in Neurological Disorders. 2018 May 20
• 2 citations
  Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an ...
  Anthony Traboulsee, David K.B. Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller> ;BMC Neurology. 2018 May 11
• 12 citations
  First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relaps...
  Bruce Hughes, Mark Cascione, Mark S. Freedman, Mark A. Agius, Daniel Kantor, Mark Gudesblatt, Lawrence P. Goldstick, Neetu Agashivala, Lesley Schofield, Kevin McCague,...> ;Multiple Sclerosis and Related Disorders. 2014 Sep 1
• 6 citations
  Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis...
  Mark Cascione, Daniel Wynn, Luigi Barbato, Linda Pestreich, Lesley Schofield, Kevin McCague> ;Journal of Medical Economics. 2013 May 6
• 8 citations
  Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized...
  Barry A Singer, Daniel Bandari, Mark Cascione, Christopher LaGanke, John Huddlestone, Randy Bennett, Fernando Dangond> ;BMC Neurology. 2012 Dec 6
• 12 citations
  Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
  Barry A Singer, Sibyl Wray, T. Miller, M. Cascione, A. Gupta, Gabriel Pardo, Watsky Eric Jacob, Brooke Hayward, B. Mercer, Fernando Dangond> ;Multiple Sclerosis and Related Disorders. 2012 Apr 1
• Join now to see all